Indrayani Biotech Limited has fulfilled its quarterly regulatory obligations by submitting the mandatory compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission demonstrates the company's adherence to securities market regulations governing dematerialization processes.

Regulatory Compliance Submission

The company submitted its Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 4, 2026. The certificate was addressed to both major depositories in India - National Securities Depository Limited and Central Depository Services (India) Limited. Company Secretary and Compliance Officer Ramya Ravi signed the submission letter on behalf of Indrayani Biotech Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, served as the Registrar and Transfer Agent for this compliance process. The RTA issued its confirmation certificate on April 3, 2026, one day prior to the company's submission to the depositories. Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, signed the confirmation certificate.

Compliance Confirmations

The RTA certificate confirmed several critical compliance aspects for the quarter ended March 31, 2026:

• Securities received from depository participants for dematerialization were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were confirmed or rejected within prescribed timelines
• Received security certificates were mutilated and cancelled after due verification by the depository participant
• Names of the depositories were substituted in the register of members as registered owners within prescribed timelines

Stakeholder Notifications

The company ensured comprehensive stakeholder communication by copying BSE Limited on the submission. The notification was sent to BSE's Department of Corporate Services at their Dalal Street, Mumbai office, maintaining transparency with the listing authority regarding the compliance certification process.

This quarterly submission represents standard regulatory practice for listed companies, ensuring proper oversight of dematerialization activities and maintaining investor confidence in the securities handling process.

Indrayani Biotech Limited's Board of Directors has formally accepted the resignation of its Whole-time Director following the scheduled Board meeting. The Company received the resignation letter on March 19, 2026, and has now completed the formal acceptance process as per regulatory requirements.

Director Resignation and Board Acceptance

The Board of Directors, at its meeting held on March 24, 2026, formally accepted the resignation of Mr. Singarababu Indirakumar from his position as Whole-time Director. The resignation details and timeline are as follows:

Mr. Singarababu Indirakumar has been relieved from his duties effective from the close of business hours on March 24, 2026. The director had originally tendered his resignation on March 16, 2026, which the Company received on March 19, 2026.

Board Meeting Proceedings

The Board meeting was conducted as scheduled on March 24, 2026, at 11:00 AM at the Company's registered office. During the meeting, the Board deliberated on the resignation letter and formally accepted the resignation as submitted. The Company Secretary, Ramya Ravi, communicated the Board's decision to the BSE on the same day.

Prior to the Board meeting, Mr. Indirakumar had sent an email on March 20, 2026, clarifying that the Board meeting notice was not applicable to him as he had already resigned on March 16, 2026, with intimation to the Registrar of Companies and other relevant authorities.

Regulatory Compliance and Disclosure

Indrayani Biotech has maintained full regulatory compliance throughout this transition process. The Company has fulfilled its obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by providing timely disclosures to the BSE.

The Company has provided comprehensive details in Annexure-I, including the director's name, DIN, designation, reason for change, and effective dates as required under the relevant SEBI circulars and regulations. This ensures complete transparency with stakeholders and maintains the Company's commitment to regulatory compliance during leadership transitions.